The National Institute of Dental and Craniofacial Research has provided a $3.24 million grant to investigate an injectable biomaterial designed to deliver immunotherapy directly to oral cancer tumors.
The biomaterial, SABERGel, combines four therapeutic functions within the tumor environment, aiming to prevent cancer recurrence and overcome the tumor’s ability to suppress the body’s immune response, according to a Nov. 16 news release from UTHealth Houston.
The peptide-based hydrogel is designed to allow different agents to be released at different rates, coordinating the recruitment and activation of cancer-fighting immune cells while blocking biological pathways that suppress their activity.
Simon Young, DDS, MD, PhD, of the UTHealth Houston School of Dentistry is a co-principal investigator along with Jeffrey Hartgerink, PhD, of Rice University, and Andrew Sikora, MD, PhD, of The University of Texas MD Anderson Cancer Center.
The project is scheduled to run through June 2031. By the end of the five-year project, the research team hopes to identify promising hydrogel formulations and establish the preclinical evidence needed to guide further development toward potential testing in patients, the release said.
